<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999504</url>
  </required_header>
  <id_info>
    <org_study_id>FDS-BNH-1268</org_study_id>
    <nct_id>NCT01999504</nct_id>
  </id_info>
  <brief_title>Gut Hormone Response After Paleolithic-type Meals</brief_title>
  <acronym>FooA2</acronym>
  <official_title>Gut Hormone Response After Two Paleolithic-type Meals Compared to a Modern-type Meal Composed According to WHO Guidelines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unilever R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leatherhead Food Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Unilever R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of two palaeolithic-type meals will be assessed with respect to a panel of gut
      hormones, satiety, blood glucose and insulin levels as compared to a meal constructed along
      the lines of the world Health Organisation dietary recommendations
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the current study the effects of two palaeolithic-type meals will be assessed with respect
      to a panel of gut hormones (including incretins), satiety, blood glucose and insulin levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon-like peptide-1</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Area under the Concentration versus time curve for Glucagon-like peptide-1 in blood plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose-dependent Insulinotropic Peptide</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Area under the Concentration versus time curve of Glucose-dependent Insulinotropic Peptide in blood plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fullness</measure>
    <time_frame>0-4 hours</time_frame>
    <description>Area under the curve for fullness scores (as rated by the subjects on a Visual Analog Scale) versus time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Area under the Concentration versus time curve of Glucose in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Area under the Concentration versus time curve of insulin in blood plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Area under the Concentration versus time curve of Glucagon in blood plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peptide YY</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Area under the Concentration versus time curve of Peptide YY in blood plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hunger</measure>
    <time_frame>0-4 hours</time_frame>
    <description>Area under the curve for hunger scores (as rated by the subjects on a Visual Analog Scale) versus time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desire to eat</measure>
    <time_frame>0-4 hours</time_frame>
    <description>Area under the curve for desire to eat scores (as rated by the subjects on a Visual Analog Scale) versus time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Insulin/glucose ratio</measure>
    <time_frame>30 minutes</time_frame>
    <description>Ratio between insulin and glucose in blood as measured at 30 minutes after start of test product intake</description>
  </other_outcome>
  <other_outcome>
    <measure>Ad libitum meal</measure>
    <time_frame>4 hours</time_frame>
    <description>Weight of an ad libitum pasta with tomato sauce meal consumed at 4 hours after test product intake</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to return to baseline of satiety score for fullness, hunger and desire to eat</measure>
    <time_frame>up to 4 hours</time_frame>
    <description>Time to return to baseline for the scores on a Visual Analogue Scales for fullness, hunger and desire to eat</description>
  </other_outcome>
  <other_outcome>
    <measure>Peptide hormones</measure>
    <time_frame>0-3 hours</time_frame>
    <description>Area under the Concentration versus time curve for total amylin, ghrelin, pancreatic polypeptide, C-peptide, leptin, interleukin-6, monocyte chemotactic protein-1 and tumour necrosis factor-alpha in blood plasma</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Satiety</condition>
  <arm_group>
    <arm_group_label>PAL-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times (e.g. no cereals, no dairy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TFH-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times, (e.g. no cereals, no dairy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Meal based on WHO dietary guidelines for protein, fat and carbohydrate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PAL-2</intervention_name>
    <description>meal</description>
    <arm_group_label>PAL-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TFH-1</intervention_name>
    <description>Meal</description>
    <arm_group_label>TFH-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reference</intervention_name>
    <description>Meal</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) 18-27 inclusive

          -  Apparently healthy: no medical conditions which might affect study measurements as
             judged by Leatherhead physician based on a health questionnaire)

          -  Having general practitioner

          -  Reported dietary habits: no medically prescribed diet, no slimming diet, used to eat 3
             meals a day, no vegetarian

          -  Reported intense sporting activities less than 10h/w

          -  Reported alcohol consumption less than 21units/w

          -  non-smoking

          -  A fasting capillary blood glucose value within the local normal reference value: 4-6.5
             mmol/L measured by finger prick

        Exclusion Criteria:

          -  Use of medication which interferes with the study measurements (as judged by the study
             physician)

          -  Being an employee of Unilever or Leatherhead Food Research

          -  Scoff questionaire score ≥ 2

          -  Eating habit questionnaire ≥ 14

          -  Smoking

          -  Dislike, allergy or intolerance t the test meals or the ad libitum meal

          -  Reported participation in another nutritional or biomedical trial 3 months before
             pre-study examination or during the study

          -  Reported participation in night shift work two weeks prior to the pre-study
             investigation during the study. Night work is defined as working between midnight and
             06.00 AM
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Diaz-Toledo Trenado</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leatherhead Food Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leatherhead Food Research</name>
      <address>
        <city>Leatherhead</city>
        <state>Surrey</state>
        <zip>KT22 7RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <last_update_submitted>October 16, 2014</last_update_submitted>
  <last_update_submitted_qc>October 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucagon-like peptide-1</keyword>
  <keyword>Glucose-dependent Insulinotropic Peptide</keyword>
  <keyword>Peptide YY</keyword>
  <keyword>Glucagon</keyword>
  <keyword>Satiety</keyword>
  <keyword>Meal</keyword>
  <keyword>palaeolithic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

